A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy

Politi, Angeliki Louiza

Home
→
Treballs d'estudiants
→
Treballs de la UPF Barcelona School of Management
→
Online Master in Health Economics and Pharmacoeconomics
→
View Item

A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy

Document Type: Master Thesis

Date: 2021

This document is associated with a Creative Common license

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Name: Louiza_ACS_MUESIO ...

Size: 427.9Kb

Format: PDF

View/Open

Citation: Politi, Angeliki Louiza. A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy. 2021
http://hdl.handle.net/10230/46867

Permanent link: http://hdl.handle.net/10230/46867

Description:

Master in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) Curs 2018-2021

Mentor: Carlos Crespo

Abstract:

The purpose of this study is to conclude as to whether it is cost-effective to introduce genotyping in the Norwegian clinical practice in the case of acute coronary syndrome, as a guide of pharmacotherapy decision making after a percutaneous coronary intervention.

Author: Politi, Angeliki Louiza

Show full item record